Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-11-22
2000-06-06
Brusca, John S.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
4242771, 435 6, 4353201, 435325, 435353, 514 44, 536 231, 536 2431, 536 245, A61K 4800, A61K 3512, C12N 1585, C07H 2104
Patent
active
060718919
ABSTRACT:
A composition and method for inhibiting the growth and metastasis of breast tumors, including a tumor immunogen derived from breast tumor cells treated with an antisense oligonucleotide complementary to a gene or mRNA for the receptor for insulin-like growth factor type 1.
REFERENCES:
patent: 5643788 (1997-07-01), Baserga et al.
Resnicoff et al., Rat Glioblastoma Cells Expressing an Antisense RNA to the Insulin-Like Growth Factor-1 (IGF-1) Receptor are Nontumorigenic and Induce Regression of Wild-Type Tumors, Cancer Res. 54, 2218-2222 (1994).
Burfeind et al., Antisense RNA to the Type I Insulin-Like Growth Factor Receptor Suppresses Tumor Growth and Prevents Invasion by Rat Prostate Cancer Cells in Vivo, PNAs 93, 7263-7268 (Jul. 1996).
Gilboa, Immunotherapy of Cancer with Genetically Modified Tumor Vaccines, Seminars in Oncology 23 (1) 101-107 (Feb. 1996).
Calabretta, et al., 1993, Cancer Treatment Reviews, 19:169-179, "Prospects for gene-directed therapy with antisense oligodeoxynucleotides".
Carter and Lemoine, 1993, Br. J. Cancer, 67:869-876, Antisense technology for cancer therapy: does it make sense?.
Hall, et al., 1996 (Feb.), Neurosurgery, 38:2:376-383, "Antisense Oligonucleotides for Central Nervous System Tumors".
Leonetti, et al., 1993, Progress in Nucleic Acid Research, pp. 143-166, "Cell Delivery and Mechanisms of Action of Antisense Oligonucleotides".
Resnicoff, et al., 1993, Laboratory Investigation, 69:6:756-760, "Insulin-like Growth Factor-1 and its Receptor Mediate the Autocrine Proliferation of Human Ovarian Carcinoma Cell Lines".
Resnicoff, et al., Apr. 15, 1994, Cancer Research, 54:2218-2222 "Rat Glioblastoma Cells Expressing an Antisense RNA to the Insulin-like Growth Factor-1 (IGF-1) Receptor Are Nontumorigenic and Induce Regression of Wild-Type Tumores".
Resnicoff, et al., Sep. 15, 1994, Cancer Research, 54:4848-4850, "Growth Inhibition of Human Melanoma Cells in Nude Mice by Antisense Strategies to the Type 1 Insulin-like Growth Factor Receptor".
Resnicoff, et al., Jun. 1, 1995, Cancer Research, 55:2463-2469, "The Insulin-like Growth Factor I Receptor Protects Tumor Cells from Apoptosis in Vivo".
Resnicoff, et al., Sep. 1, 1995, Cancer Research, 55:373903741, "Correlation between Apoptosis, Tumorigenesis, and Levels of Insulin-like Growth Factor I Receptors".
Resnicoff, et al., 1996, Cancer Immunol Immunother, 42:64-68, "Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA".
Sell, et al., Jan. 15, 1995, Cancer Research, 55:303-306, "Insulin-like Growth Factor I (IGE-I) and the IGF-I Receptor Prevent Etoposide-induced Apoptosis".
Stein and Chang, Aug. 20, 1993, Science 261:1004-1011, "Antisense Oligonucleotides as Therapeutic Agents--Is the Bullet Really Magical?".
Trojan, et al., Jun. 1992, Proc. Natl. Acad. Sci, USA, 89:4874-4878, "Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I".
Trojan, et al., Jan. 1, 1993, Science, 259:94-97, "Treatment and Prevention of Rat Glioblastoma by Immunogenic C6 Cells Expressing Antisense Insulin-Like Growth Factor I RNA".
Trojan, et al., Jun. 1994, Proc. Natl. Acad. Sci. USA, 91:6088-6092, "Gene therapy of murine teratocarcinoma: Separate functions for insulin-like growth factors I and II in immunogenicity and differentiation".
Wallenfriedman, et al., 1996, Abstract--AACR--Effects of IGF-1R antisense and nonsense oligonucleotide administration on 9L glioblastoma and MAT B3 breast tumor growth in Fischer 344 rats.
Baserga, R., "Controlling IGF-receptor function: a possible strategy for tumor therapy", TIBTECH, 14: 150-152 (May 1996).
Wallenfriedman, M.A. et al., "IGF-1 R Antisense and Nonsense Oligonucleotide Therapy for 9L Glioblastoma Results in an Immune Response Against an Unrelated Syngeneic Tumor in Fischer 344 Rats", Society for Neuroscience, 22: 1 page (1966).
"Experimental Therapeutics", Proceedings of the American Association for Cancer Research, 37: Cover and p. 354 (Mar. 1996).
"Immunology/Preclinical and Clinical Biological Therapy", Proceedings of the American Association for Cancer Research, 38: Cover and p. 617 (Mar. 1997).
Chiang Lan
Low Walter C.
Wallenfriedman Margaret A.
Brusca John S.
Regents of the University of Minnesota
Shibuya Mark L.
LandOfFree
Insulin-like growth factor 1 receptors (IGF-1R) antisense oligon does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Insulin-like growth factor 1 receptors (IGF-1R) antisense oligon, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Insulin-like growth factor 1 receptors (IGF-1R) antisense oligon will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2213672